1887

Abstract

Protozoan parasites of the genus are the causative agents of life-threatening visceral as well as cutaneous and mucocutaneous leishmaniasis. First-line drugs are antimonials, but toxicity and resistance in some endemic areas cause serious problems. In the current study, the antileishmanial activity of the weak oxidant -chlorotaurine (NCT) was investigated. NCT is a derivative of the amino acid taurine produced by granulocytes and monocytes during oxidative burst, but can also be synthesized chemically and used topically as an antiseptic at a concentration of 1 % (55 mM) . NCT susceptibility tests were performed with promastigotes and amastigotes of and . As NHCl is known to increase the activity of NCT by the formation of monochloramine (NHCl), co-treatment assays were included in the study. Mean EC values after 1 h of treatment were 5.94 mM for and 9.8 mM for promastigotes. Co-treatment with 5.5 mM NCT plus 19 mM NHCl led to complete killing of promastigotes of both strains within 15 min. Amastigotes were inactivated by treatment with 2 mM NCT alone. The results of this study indicate a high potential of NCT against species.

Keyword(s): NCT, N-chlorotaurine
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.011155-0
2009-10-01
2021-10-20
Loading full text...

Full text loading...

/deliver/fulltext/jmm/58/10/1298.html?itemId=/content/journal/jmm/10.1099/jmm.0.011155-0&mimeType=html&fmt=ahah

References

  1. Arnitz R., Sarg B., Ott H. W., Neher A., Lindner H., Nagl M. 2006; Protein sites of attack of N -chlorotaurine in Escherichia coli . Proteomics 6:865–869 [CrossRef]
    [Google Scholar]
  2. Ashutosh Sundar S., Goyal N. 2007; Molecular mechanisms of antimony resistance in Leishmania . J Med Microbiol 56:143–153 [CrossRef]
    [Google Scholar]
  3. Beach D. H., Holz G. G. Jr, Anekwe G. E. 1979; Lipids of Leishmania promastigotes. J Parasitol 65:201–216
    [Google Scholar]
  4. Collin S., Davidson R., Ritmeijer K., Keus K., Melaku Y., Kipngetich S., Davies C. 2004; Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan. Clin Infect Dis 38:612–619 [CrossRef]
    [Google Scholar]
  5. Croft S. L., Sundar S., Fairlamb A. H. 2006; Drug resistance in leishmaniasis. Clin Microbiol Rev 19:111–126 [CrossRef]
    [Google Scholar]
  6. Eibl H. 2000; Tödliche Tropenkrankheit jetzt heilbar. (accessed 12 February 2009 http://www.mpibpc.gwdg.de/abteilungen/293/PR/00_01/leish.html
  7. Escobar P., Matu S., Marques C., Croft S. L. 2002; Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Trop 81:151–157 [CrossRef]
    [Google Scholar]
  8. Fürnkranz U., Nagl M., Gottardi W., Köhsler M., Aspöck H., Walochnik J. 2008; Cytotoxic activity of N -chlorotaurine on Acanthamoeba spp. Antimicrob Agents Chemother 52:470–476 [CrossRef]
    [Google Scholar]
  9. Gebre-Hiwot A., Tadesse G., Croft S. L., Frommel D. 1992; An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1. Acta Trop 51:237–245 [CrossRef]
    [Google Scholar]
  10. Gottardi W., Nagl M. 2002; Chemical properties of N -chlorotaurine sodium, a key compound in the human defence system. Arch Pharm (Weinheim 335:411–421 [CrossRef]
    [Google Scholar]
  11. Gottardi W., Nagl M. 2005; Chlorine covers on living bacteria: the initial step in antimicrobial action of active chlorine compounds. J Antimicrob Chemother 55:475–482 [CrossRef]
    [Google Scholar]
  12. Gottardi W., Hagleitner M., Nagl M. 2001; The influence of plasma on the disinfecting activity of the new antimicrobial agent N -chlorotaurine-sodium in comparison with chloramine T. J Pharm Pharmacol 53:689–697 [CrossRef]
    [Google Scholar]
  13. Gottardi W., Arnitz R., Nagl M. 2007; N -Chlorotaurine and ammonium chloride: an antiseptic preparation with strong bactericidal activity. Int J Pharm 335:32–40 [CrossRef]
    [Google Scholar]
  14. Grimm F., Brun R., Jenni L. 1991; Promastigote infectivity in Leishmania infantum . Parasitol Res 77:185–191 [CrossRef]
    [Google Scholar]
  15. Hofer E., Neher A., Gunkel A. R., Nagl M. 2003; In vitro study on the influence of N -chlorotaurine on the ciliary beat frequency of nasal mucosa. Am J Rhinol 17:149–152
    [Google Scholar]
  16. Hofman V., Marty P., Perrin C., Saint-Paul M. C., Le Fichoux Y., Michiels J. F., Glaichenhaus N., Pratlong F., Hofman P. 2000; The histological spectrum of visceral leishmaniasis caused by Leishmania infantum MON-1 in acquired immune deficiency syndrome. Hum Pathol 31:75–84 [CrossRef]
    [Google Scholar]
  17. Kontny E., Grabowska A., Kowalczewski J., Kurowska M., Janicka I., Marcinkiewicz J., Maśliński W. 1999; Taurine chloramine inhibition of cell proliferation and cytokine production by rheumatoid arthritis fibroblast-like synoviocytes. Arthritis Rheum 42:2552–2560 [CrossRef]
    [Google Scholar]
  18. Marcinkiewicz J., Grabowska A., Bereta J., Stelmaszynska T. 1995; Taurine chloramine, a product of activated neutrophils, inhibits in vitro the generation of nitric oxide and other macrophage inflammatory mediators. J Leukoc Biol 58:667–674
    [Google Scholar]
  19. Mathur P., Samantaray J. C., Vajpayee M., Samanta P. 2006; Visceral leishmaniasis/human immunodeficiency virus co-infection in India: the focus of two epidemics. J Med Microbiol 55:919–922 [CrossRef]
    [Google Scholar]
  20. Nagl M., Gottardi W. 1996; Enhancement of the bactericidal efficacy of N -chlorotaurine by inflammation samples and selected N-H compounds. Hyg Med 21:597–605
    [Google Scholar]
  21. Nagl M., Larcher C., Gottardi W. 1998a; Activity of N -chlorotaurine against herpes simplex- and adenoviruses. Antiviral Res 38:25–30 [CrossRef]
    [Google Scholar]
  22. Nagl M., Miller B., Daxecker F., Ulmer H., Gottardi W. 1998b; Tolerance of N -chlorotaurine, an endogenous antimicrobial agent, in the rabbit and human eye – a phase I clinical study. J Ocul Pharmacol Ther 14:283–290 [CrossRef]
    [Google Scholar]
  23. Nagl M., Pfausler B., Schmutzhard E., Fille M., Gottardi W. 1998c; Tolerance and bactericidal action of N -chlorotaurine in a urinary tract infection by an omniresistant Pseudomonas aeruginosa . Zentralbl Bakteriol 288:217–223 [CrossRef]
    [Google Scholar]
  24. Nagl M., Hess M. W., Pfaller K., Hengster P., Gottardi W. 2000; Bactericidal activity of micromolar N -chlorotaurine: evidence for its antimicrobial function in the human defense system. Antimicrob Agents Chemother 44:2507–2513 [CrossRef]
    [Google Scholar]
  25. Nagl M., Lass-Floerl C., Neher A., Gunkel A. R., Gottardi W. 2001; Enhanced fungicidal activity of N -chlorotaurine in nasal secretion. J Antimicrob Chemother 47:871–874 [CrossRef]
    [Google Scholar]
  26. Nagl M., Nguyen V. A., Gottardi W., Ulmer H., Höpfl R. 2003; Tolerability and efficacy of N -chlorotaurine in comparison with chloramine T for the treatment of chronic leg ulcers with a purulent coating: a randomized phase II study. Br J Dermatol 149:590–597 [CrossRef]
    [Google Scholar]
  27. Park E., Schuller-Levis G., Quinn M. R. 1995; Taurine chloramine inhibits production of nitric oxide and TNF- α in activated RAW 264.7 cells by mechanisms that involve transcriptional and translational events. J Immunol 154:4778–4784
    [Google Scholar]
  28. Reeves E. P., Nagl M., O'Keeffe J., Kelly J., Kavanagh K. 2006; Effect of N -chlorotaurine on Aspergillus , with particular reference to destruction of secreted gliotoxin. J Med Microbiol 55:913–918 [CrossRef]
    [Google Scholar]
  29. Singh S. P., Reddy D. C., Rai M., Sundar S. 2006; Serious underreporting of visceral leishmaniasis through passive case reporting in Bihar, India. Trop Med Int Health 11:899–905 [CrossRef]
    [Google Scholar]
  30. Sundar S., Rai M. 2005; Treatment of visceral leishmaniasis. Expert Opin Pharmacother 6:2821–2829 [CrossRef]
    [Google Scholar]
  31. Teuchner B., Nagl M., Schidlbauer A., Ishiko H., Dragosits E., Ulmer H., Aoki K., Ohno S., Mizuki N. other authors 2005; Tolerability and efficacy of N -chlorotaurine in epidemic keratoconjunctivitis – a double-blind, randomized, phase-2 clinical trial. J Ocul Pharmacol Ther 21:157–165 [CrossRef]
    [Google Scholar]
  32. Yardley V., Croft S. L., De Doncker S., Dujardin J. C., Koirala S., Rijal S., Miranda C., Llanos-Cuentas A., Chappuis F. 2005; The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg 73:272–275
    [Google Scholar]
  33. Yazdanbakhsh M., Eckmann C. M., Roos D. 1987; Killing of schistosomula by taurine chloramine and taurine bromamine. Am J Trop Med Hyg 37:106–110
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.011155-0
Loading
/content/journal/jmm/10.1099/jmm.0.011155-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error